Literature DB >> 26183316

Lack of galectin-3 improves the functional outcome and tissue sparing by modulating inflammatory response after a compressive spinal cord injury.

Klauss Mostacada1, Felipe L Oliveira2, Déa M S Villa-Verde3, Ana Maria Blanco Martinez4.   

Abstract

Spinal cord injury (SCI) is a traumatic event that results in motor, sensitive or autonomic function disturbances, which have direct impact on the life quality of the affected individual. Recent studies have shown that attenuation of the inflammatory response after SCI plays a key role in the reestablishment of motor function. Galectin-3 is a pleiotropic molecule belonging to the carbohydrate-ligand lectin family, which is expressed by different cells in different tissues. Studies have shown that galectin-3 induces the recruitment and activation of neutrophils, monocytes/macrophages, lymphocytes and microglia. Thus, the aim of this study was to evaluate the effects of the lack of galectin-3 on the functional outcome, cellular recruitment and morphological changes in tissue, after SCI. C57BL/6 wild-type and galectin-3 knockout mice were used in this study. A vascular clip was used for 1 min to generate a compressive SCI. By BMS we detected that the Gal-3(-/-) presented a better functional outcome during the studied period. This finding is related to a decrease in the injury length and a higher volume of spared white matter at 7 and 42 days post injury (dpi). Moreover, Gal-3(-/-) mice showed a higher number of spared fibers at 28 dpi. Because of the importance of the inflammatory response after SCI and the role that galectin-3 plays in it, we investigated possible differences in the inflammatory response between the analyzed groups. No differences in neutrophils were observed 24h after injury. However, at 3 dpi, the Gal-3(-/-) mice showed more neutrophils infiltrated into the spinal tissue when compared with the WT mice. At this same time point, no differences in the percentage of the CD11b/Arginase1 positive cells were observed. Remarkably, Gal-3(-/-) mice displayed a decrease in CD11b staining at 7 dpi, compared with the WT mice. At the same time, Gal-3(-/-) mice presented a more prominent Arginase1 stained area, suggesting an anti-inflammatory cell phenotype. Taken together, these results demonstrated that the lack of galectin-3 plays a key role in the inflammatory process triggered by SCI, leading to better and early recovery of locomotor function.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Galectin-3; Macrophages; Mice; Microglia; Neuroinflammation; Neutrophils; Spinal cord injury (SCI)

Mesh:

Substances:

Year:  2015        PMID: 26183316     DOI: 10.1016/j.expneurol.2015.07.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  17 in total

Review 1.  Immunobiology of spinal cord injuries and potential therapeutic approaches.

Authors:  Aabra Ahmed; Arun-Angelo Patil; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-09-07       Impact factor: 3.396

2.  Genetic deletion of galectin-3 enhances neuroinflammation, affects microglial activation and contributes to sub-chronic injury in experimental neonatal focal stroke.

Authors:  Sophorn Chip; David Fernández-López; Fan Li; Joel Faustino; Nikita Derugin; Zinaida S Vexler
Journal:  Brain Behav Immun       Date:  2016-11-09       Impact factor: 7.217

3.  Absence of galectin-3 attenuates neuroinflammation improving functional recovery after spinal cord injury.

Authors:  Caio Andrade Prins; Fernanda Martins Almeida; Ana Maria Blanco Martinez
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

4.  Galectin-3 Negatively Regulates Hippocampus-Dependent Memory Formation through Inhibition of Integrin Signaling and Galectin-3 Phosphorylation.

Authors:  Yan-Chu Chen; Yun-Li Ma; Cheng-Hsiung Lin; Sin-Jhong Cheng; Wei-Lun Hsu; Eminy H-Y Lee
Journal:  Front Mol Neurosci       Date:  2017-07-11       Impact factor: 5.639

5.  Past, present and future of preserving and restoring function in the visual system: removing galectin-3 as a promising treatment.

Authors:  Silmara de Lima; Henrique Rocha Mendonça; Camila Oliveira Goulart; Ana M Blanco Martinez
Journal:  Neural Regen Res       Date:  2017-01       Impact factor: 5.135

6.  Genetic and Pharmacological Inhibition of p38α Improves Locomotor Recovery after Spinal Cord Injury.

Authors:  Hiroki Umezawa; Yusuke Naito; Kensuke Tanaka; Kento Yoshioka; Kenichi Suzuki; Tatsuhiko Sudo; Masahiko Hagihara; Masahiko Hatano; Koichiro Tatsumi; Yoshitoshi Kasuya
Journal:  Front Pharmacol       Date:  2017-02-17       Impact factor: 5.810

7.  Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration.

Authors:  Ping Kei Yip; Alejandro Carrillo-Jimenez; Paul King; Anna Vilalta; Koji Nomura; Chi Cheng Chau; Alexander Michael Scott Egerton; Zhuo-Hao Liu; Ashray Jayaram Shetty; Jordi L Tremoleda; Meirion Davies; Tomas Deierborg; John V Priestley; Guy Charles Brown; Adina Teodora Michael-Titus; Jose Luis Venero; Miguel Angel Burguillos
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 8.  The Sweet-Side of Leukocytes: Galectins as Master Regulators of Neutrophil Function.

Authors:  Brian S Robinson; Connie M Arthur; Birk Evavold; Ethan Roback; Nourine A Kamili; Caleb S Stowell; Mary L Vallecillo-Zúniga; Pam M Van Ry; Marcelo Dias-Baruffi; Richard D Cummings; Sean R Stowell
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 8.786

9.  Associations of Small Fiber Neuropathy with Geriatric Nutritional Risk Index and Arterial Stiffness in Hemodialysis.

Authors:  Mei-Chuan Kuo; Jiun-Chi Huang; Pei-Yu Wu; Hsiu-Chin Mai; Szu-Chia Chen; Yi-Wen Chiu; Jer-Ming Chang; Hung-Chun Chen
Journal:  Dis Markers       Date:  2020-05-19       Impact factor: 3.434

Review 10.  Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior.

Authors:  Ivan Srejovic; Dragica Selakovic; Nemanja Jovicic; Vladimir Jakovljević; Miodrag L Lukic; Gvozden Rosic
Journal:  Biomolecules       Date:  2020-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.